<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00447382</url>
  </required_header>
  <id_info>
    <org_study_id>EX1729-1778</org_study_id>
    <secondary_id>2006-004733-15</secondary_id>
    <nct_id>NCT00447382</nct_id>
  </id_info>
  <brief_title>Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes</brief_title>
  <official_title>A 12-months Multi-national, Multi-centre, Double Blind, Randomised, Parallel Safety and Efficacy Comparison of Insulin Detemir Produced by the Current Process and Insulin Detemir Produced by the NN729 Process in Subjects With Type 1 Diabetes on a Basal-bolus Regimen With Insulin Aspart as the Bolus Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial was conducted in Germany, The Republic of Macedonia, Russian Federation, Serbia and
      South Africa. The aim of this trial was to make a safety comparison of insulin detemir
      produced by a new production method (NN729) with insulin detemir made by the previous
      production method (NN304). Subjects were treated with NN729 or NN304 for a period of 52 weeks
      at the same total daily dose and frequency of administration as their own pre-trial basal
      insulin . During the trial doses were individualised based on subject's plasma glucose
      measurements.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Insulin Detemir - Human Insulin Cross-reacting Antibodies</measure>
    <time_frame>week 0, week 52</time_frame>
    <description>Measured change in concentrations of insulin detemir cross-reacting antibodies and the change ratio from baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycaemic Episodes</measure>
    <time_frame>Weeks 0-52</time_frame>
    <description>Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. Hypoglycaemic episodes occurring in the time frame between 23:00 hours (included) and 06:00 hours (excluded) were defined as nocturnal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycaemic Control Parameters (Change in HbA1c)</measure>
    <time_frame>week 0, week 52</time_frame>
    <description>HbA1c (Glycosylated haemoglobin).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycaemic Control Parameters (Change in Fasting Plasma Glucose [FPG])</measure>
    <time_frame>week 0, week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycaemic Control Parameters (9-point Self Measured Plasma Glucose [SMPG])</measure>
    <time_frame>week 0, 26 and 52</time_frame>
    <description>point is Before Breakfast
point is 120 minutes after Breakfast
point is Before Lunch
point is 120 minutes after Lunch
point is Before Dinner
point is 120 minutes after Dinner
point is at Bedtime
point is At 03:00 A.M.
point is Before Breakfast the Following Day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Detemir Specific Antibodies</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Measured change in concentrations of antibody values for insulin detemir specific antibodies and the change ratio from the baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Antibodies</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Measured change in concentrations of total insulin antibodies values (the sum of insulin detemir specific and insulin detemir - human insulin cross-reacting antibodies) and the change ratio from baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Haematology - Basophilis)</measure>
    <time_frame>week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Haematology - Eosinophils)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Haematology - Haemoglobin)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Haematology - Lymphocytes)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Haematology - Monocytes)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Haematology - Neutrophils)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Haematology - Thrombocytes)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Haematology - Leucocytes)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Biochemistry - Albumin)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Biochemistry - Alanine Aminotransferase [ALAT])</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.
(ALAT = alanine aminotransferase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Biochemistry - Alkaline Phosphatase [ALP])</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.
(ALP = alkaline phosphatase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Biochemistry - Creatinine)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Biochemistry - Lactate Dehydrogenase [LDH])</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory (LDH = lactate dehydrogenase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Biochemistry - Potassium)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Biochemistry - Sodium)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Values (Change in Biochemistry - Total Protein)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Weeks 0-52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>NN304</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NN729</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin detemir</intervention_name>
    <description>NN304 injected s.c. (under the skin). Given as basal insulin.</description>
    <arm_group_label>NN304</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin aspart</intervention_name>
    <description>Injected s.c. (under the skin). Given as bolus insulin.</description>
    <arm_group_label>NN304</arm_group_label>
    <arm_group_label>NN729</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin detemir</intervention_name>
    <description>NN729 injected s.c. (under the skin). Given as basal insulin</description>
    <arm_group_label>NN729</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes for at least 12 months

          -  Basal-bolus treatment for at least 3 months

          -  Body Mass Index (BMI) less than or equal to 35.0 kg/m^2

          -  HbA1c (glycosylated haemoglobin) less than or equal to 12.0%

        Exclusion Criteria:

          -  Known or suspected allergy to trial products or related products

          -  Pregnancy, breast-feeding or the intention to become pregnant or not using adequate
             contraceptive measures

          -  Receipt of any trial drug within 1 month prior to this trial

          -  Mental incapacity, unwillingness or language barriers precluding adequate
             understanding or cooperation

          -  Conditions that may interfere with trial participation as judged by Investigator:
             proliferative retinopathy or maculopathy requiring acute treatment within the last six
             months, recurrent major hypoglycaemia, impaired hepatic or renal function, cardiac
             problems, uncontrolled hypertension (treated and untreated)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Former Serbia and Montenegro</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>119034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Former Serbia and Montenegro</country>
    <country>Germany</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
  </location_countries>
  <removed_countries>
    <country>San Marino</country>
    <country>Serbia</country>
  </removed_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2007</study_first_submitted>
  <study_first_submitted_qc>March 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2007</study_first_posted>
  <results_first_submitted>November 24, 2010</results_first_submitted>
  <results_first_submitted_qc>May 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2011</results_first_posted>
  <disposition_first_submitted>October 29, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>October 29, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 2, 2010</disposition_first_posted>
  <last_update_submitted>October 8, 2014</last_update_submitted>
  <last_update_submitted_qc>October 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twenty four sites in five countries: Germany (12), The Republic of Macedonia (1), Russian Federation (4), Serbia (3) and South Africa (4)</recruitment_details>
      <pre_assignment_details>Eligible subjects were adults with type 1 diabetes treated with a basal-bolus regimen for at least 3 months prior to the study, who had a BMI (Body Mass Index) no greater than 35.0 kg/m^2 and HbA1c no greater than 12.0%.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NN304</title>
          <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>NN729</title>
          <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NN304</title>
          <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>NN729</title>
          <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="166"/>
            <count group_id="B3" value="330"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.9" spread="14.9"/>
                    <measurement group_id="B2" value="38.6" spread="13.6"/>
                    <measurement group_id="B3" value="39.3" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.74" spread="0.09"/>
                    <measurement group_id="B2" value="1.72" spread="0.1"/>
                    <measurement group_id="B3" value="1.73" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.6" spread="14.6"/>
                    <measurement group_id="B2" value="75.1" spread="14.9"/>
                    <measurement group_id="B3" value="76.4" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (Body Mass Index)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.68" spread="4.05"/>
                    <measurement group_id="B2" value="25.23" spread="3.59"/>
                    <measurement group_id="B3" value="25.45" spread="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c (Glycosylated haemoglobin)</title>
          <units>Percent (%) glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.93" spread="1.31"/>
                    <measurement group_id="B2" value="7.99" spread="1.38"/>
                    <measurement group_id="B3" value="7.96" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes History</title>
          <description>Average number of years since diagnosis</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.48" spread="11.2"/>
                    <measurement group_id="B2" value="13.66" spread="10.3"/>
                    <measurement group_id="B3" value="14.07" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Insulin Detemir – Human Insulin Cross-reacting Antibodies</title>
        <description>Measured change in concentrations of insulin detemir cross-reacting antibodies and the change ratio from baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.</description>
        <time_frame>week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Detemir – Human Insulin Cross-reacting Antibodies</title>
          <description>Measured change in concentrations of insulin detemir cross-reacting antibodies and the change ratio from baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.07"/>
                    <measurement group_id="O2" value="1.89" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis:Treatment with detemir produced with the NN729 process result in a similar change in cross reacting antibody levels as the NN304 process. Alternative hypothesis: change in antibody levels differ after treatment with detemir produced by the two manufacturing processes.
The statistical analysis applies to the change from baseline to week 52 which was analysed using ANOVA.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.649</p_value>
            <method>ANOVA</method>
            <method_desc>Treatment, previous insulin detemir exposure and country as fixed effects and the baseline value as a covariate. (Log transformed data).</method_desc>
            <param_type>Treatment Ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
            <estimate_desc>The treatment ratio calculated is the NN729-NN304 ratio for the change from baseline to Week 52. The 95% confidence interval for this ratio was also calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycaemic Episodes</title>
        <description>Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. Hypoglycaemic episodes occurring in the time frame between 23:00 hours (included) and 06:00 hours (excluded) were defined as nocturnal.</description>
        <time_frame>Weeks 0-52</time_frame>
        <population>All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycaemic Episodes</title>
          <description>Number of hypoglycaemic episodes from Week 0 to Week 52, defined as major, minor, or symptoms only. Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Symptoms only if able to treat her/himself and no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. Hypoglycaemic episodes occurring in the time frame between 23:00 hours (included) and 06:00 hours (excluded) were defined as nocturnal.</description>
          <population>All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All events - Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All events - Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3215"/>
                    <measurement group_id="O2" value="2996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All events - Symptoms Only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445"/>
                    <measurement group_id="O2" value="318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daytime - Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daytime - Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2741"/>
                    <measurement group_id="O2" value="2590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daytime - Symptoms Only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381"/>
                    <measurement group_id="O2" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal - Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal - Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="472"/>
                    <measurement group_id="O2" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nocturnal - Symptoms Only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclassified - Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycaemic Control Parameters (Change in HbA1c)</title>
        <description>HbA1c (Glycosylated haemoglobin).</description>
        <time_frame>week 0, week 52</time_frame>
        <population>All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Glycaemic Control Parameters (Change in HbA1c)</title>
          <description>HbA1c (Glycosylated haemoglobin).</description>
          <population>All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>Percent (%) glycosylated haemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.88" spread="0.07"/>
                    <measurement group_id="O2" value="7.85" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.07"/>
                    <measurement group_id="O2" value="-0.11" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis applies to the change from baseline to week 52 which was analysed using ANOVA.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.758</p_value>
            <method>ANOVA</method>
            <method_desc>Adjustments: Treatment, previous insulin detemir exposure and country as fixed effects and the baseline value as covariate.</method_desc>
            <param_type>Estimated treatment difference</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
            <estimate_desc>The estimated treatment difference calculated is the NN729-NN304 treatment difference for the change from baseline to Week 52. The 95% confidence interval for this difference was also calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycaemic Control Parameters (Change in Fasting Plasma Glucose [FPG])</title>
        <time_frame>week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Glycaemic Control Parameters (Change in Fasting Plasma Glucose [FPG])</title>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.73" spread="0.3"/>
                    <measurement group_id="O2" value="9.64" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.3"/>
                    <measurement group_id="O2" value="-0.02" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis applies to the change from baseline to week 52 which was analysed using ANOVA.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.812</p_value>
            <method>ANOVA</method>
            <method_desc>Adjustments: Treatment, previous insulin detemir exposure and country as fixed effects and the baseline value as covariate.</method_desc>
            <param_type>Estimated treatment difference</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>The estimated treatment difference calculated is the NN729-NN304 treatment difference for the change from baseline to Week 52. The 95% confidence interval for this difference was also calculated</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycaemic Control Parameters (9-point Self Measured Plasma Glucose [SMPG])</title>
        <description>point is Before Breakfast
point is 120 minutes after Breakfast
point is Before Lunch
point is 120 minutes after Lunch
point is Before Dinner
point is 120 minutes after Dinner
point is at Bedtime
point is At 03:00 A.M.
point is Before Breakfast the Following Day</description>
        <time_frame>week 0, 26 and 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Glycaemic Control Parameters (9-point Self Measured Plasma Glucose [SMPG])</title>
          <description>point is Before Breakfast
point is 120 minutes after Breakfast
point is Before Lunch
point is 120 minutes after Lunch
point is Before Dinner
point is 120 minutes after Dinner
point is at Bedtime
point is At 03:00 A.M.
point is Before Breakfast the Following Day</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline 1. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.17" spread="3.26"/>
                    <measurement group_id="O2" value="8.17" spread="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 2. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.95" spread="3.86"/>
                    <measurement group_id="O2" value="9.03" spread="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 3. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.66" spread="3.36"/>
                    <measurement group_id="O2" value="7.34" spread="3.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 4. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.60" spread="3.70"/>
                    <measurement group_id="O2" value="8.18" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 5. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.29" spread="3.37"/>
                    <measurement group_id="O2" value="8.16" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 6. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.43" spread="3.37"/>
                    <measurement group_id="O2" value="8.60" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 7. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.69" spread="3.48"/>
                    <measurement group_id="O2" value="8.60" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 8. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.97" spread="3.51"/>
                    <measurement group_id="O2" value="7.72" spread="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline 9. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.05" spread="3.49"/>
                    <measurement group_id="O2" value="7.56" spread="3.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 change. 1. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="3.95"/>
                    <measurement group_id="O2" value="-0.44" spread="4.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 change. 2. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.61" spread="4.43"/>
                    <measurement group_id="O2" value="-0.61" spread="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 change. 3. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.49" spread="3.64"/>
                    <measurement group_id="O2" value="0.08" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 change. 4. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="3.82"/>
                    <measurement group_id="O2" value="-0.22" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 change. 5. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="4.22"/>
                    <measurement group_id="O2" value="-0.00" spread="4.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 change. 6. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="4.16"/>
                    <measurement group_id="O2" value="0.07" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 change. 7. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="3.63"/>
                    <measurement group_id="O2" value="0.20" spread="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 change. 8. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="4.05"/>
                    <measurement group_id="O2" value="0.08" spread="4.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 change. 9. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="4.05"/>
                    <measurement group_id="O2" value="0.24" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 change. 1. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="4.08"/>
                    <measurement group_id="O2" value="-0.67" spread="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 change. 2. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="4.80"/>
                    <measurement group_id="O2" value="-0.99" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 change. 3. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="3.96"/>
                    <measurement group_id="O2" value="-0.28" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 change. 4. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="3.98"/>
                    <measurement group_id="O2" value="-0.29" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 change. 5. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="3.80"/>
                    <measurement group_id="O2" value="-0.59" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 change. 6. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="4.13"/>
                    <measurement group_id="O2" value="-0.51" spread="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 change. 7. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="3.92"/>
                    <measurement group_id="O2" value="-0.47" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 change. 8. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="3.59"/>
                    <measurement group_id="O2" value="-0.31" spread="3.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 change. 9. point</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="4.14"/>
                    <measurement group_id="O2" value="-0.09" spread="3.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Detemir Specific Antibodies</title>
        <description>Measured change in concentrations of antibody values for insulin detemir specific antibodies and the change ratio from the baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Detemir Specific Antibodies</title>
          <description>Measured change in concentrations of antibody values for insulin detemir specific antibodies and the change ratio from the baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="0.04"/>
                    <measurement group_id="O2" value="1.06" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis applies to the change from baseline to week 52 which was analysed using ANOVA. The analysis was based on an assumption of a log-normal distribution for antibody data and was thus built on log-transformed data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>ANOVA</method>
            <method_desc>Adjustments:Treatment, previous insulin detemir exposure and country as fixed effects and the baseline value as a covariate. (Log transformed data)</method_desc>
            <param_type>Treatment Ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>The treatment ratio calculated is the NN729-NN304 ratio for the change from baseline to Week 52. The 95% confidence interval for this ratio was also calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Antibodies</title>
        <description>Measured change in concentrations of total insulin antibodies values (the sum of insulin detemir specific and insulin detemir – human insulin cross-reacting antibodies) and the change ratio from baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Antibodies</title>
          <description>Measured change in concentrations of total insulin antibodies values (the sum of insulin detemir specific and insulin detemir – human insulin cross-reacting antibodies) and the change ratio from baseline to end of trial was calculated. The unit for measuring antibody levels is %B/T (amount of tracer bound to the antibodies in the precipitate (B) expressed in percentage of the total amount of tracer (T) added to the mixture). The change ratio does not have any unit as it is a ratio.</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="0.05"/>
                    <measurement group_id="O2" value="1.55" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The statistical analysis applies to the change from baseline to week 52 which was analysed using ANOVA. The analysis was based on an assumption of a log-normal distribution for antibody data and was thus built on log-transformed data.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.966</p_value>
            <method>ANOVA</method>
            <method_desc>Adjustments: Treatment, previous insulin detemir exposure and country as fixed effects and the baseline value as a covariate. (Log transformed data)</method_desc>
            <param_type>Treatment Ratio</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>The treatment ratio calculated is the NN729-NN304 ratio for the change from baseline to Week 52. The 95% confidence interval for this ratio was also calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Haematology - Basophilis)</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
        <time_frame>week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Haematology - Basophilis)</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>Percent (%) of white blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.67"/>
                    <measurement group_id="O2" value="0.36" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.56"/>
                    <measurement group_id="O2" value="0.33" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.50"/>
                    <measurement group_id="O2" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Haematology - Eosinophils)</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Haematology - Eosinophils)</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>Percent (%) of white blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="1.27"/>
                    <measurement group_id="O2" value="1.82" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="2.10"/>
                    <measurement group_id="O2" value="2.08" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="2.22"/>
                    <measurement group_id="O2" value="0.00" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Haematology - Haemoglobin)</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Haematology - Haemoglobin)</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.85" spread="0.92"/>
                    <measurement group_id="O2" value="8.80" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.54" spread="0.91"/>
                    <measurement group_id="O2" value="8.47" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.52"/>
                    <measurement group_id="O2" value="-0.31" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Haematology - Lymphocytes)</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Haematology - Lymphocytes)</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>Percent (%) of white blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.80" spread="6.94"/>
                    <measurement group_id="O2" value="37.45" spread="7.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.12" spread="9.17"/>
                    <measurement group_id="O2" value="36.67" spread="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.25" spread="9.18"/>
                    <measurement group_id="O2" value="5.33" spread="6.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Haematology - Monocytes)</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Haematology - Monocytes)</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage ((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>Percent (%) of white blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.40" spread="2.17"/>
                    <measurement group_id="O2" value="4.00" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" spread="2.92"/>
                    <measurement group_id="O2" value="3.42" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" spread="1.91"/>
                    <measurement group_id="O2" value="0.67" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Haematology - Neutrophils)</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Haematology - Neutrophils)</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>Percent (%) of white blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00" spread="7.51"/>
                    <measurement group_id="O2" value="56.36" spread="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.59" spread="10.75"/>
                    <measurement group_id="O2" value="57.50" spread="9.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="10.37"/>
                    <measurement group_id="O2" value="-6.00" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Haematology - Thrombocytes)</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Haematology - Thrombocytes)</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>10^9/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254.0" spread="65.5"/>
                    <measurement group_id="O2" value="267.1" spread="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="242.2" spread="58.3"/>
                    <measurement group_id="O2" value="247.2" spread="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="38.5"/>
                    <measurement group_id="O2" value="-18.6" spread="38.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Haematology - Leucocytes)</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Haematology - Leucocytes)</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants.
Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>Percent (%) of white blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.22" spread="1.91"/>
                    <measurement group_id="O2" value="6.3" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" spread="1.85"/>
                    <measurement group_id="O2" value="5.96" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.77"/>
                    <measurement group_id="O2" value="-0.32" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Biochemistry - Albumin)</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Biochemistry - Albumin)</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.30" spread="0.23"/>
                    <measurement group_id="O2" value="4.27" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.28" spread="0.25"/>
                    <measurement group_id="O2" value="4.30" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.21"/>
                    <measurement group_id="O2" value="0.02" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Biochemistry - Alanine Aminotransferase [ALAT])</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.
(ALAT = alanine aminotransferase)</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Biochemistry - Alanine Aminotransferase [ALAT])</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.
(ALAT = alanine aminotransferase)</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.21" spread="22.12"/>
                    <measurement group_id="O2" value="25.98" spread="13.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.72" spread="25.48"/>
                    <measurement group_id="O2" value="27.81" spread="16.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="17.80"/>
                    <measurement group_id="O2" value="1.76" spread="17.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Biochemistry - Alkaline Phosphatase [ALP])</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.
(ALP = alkaline phosphatase)</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Biochemistry - Alkaline Phosphatase [ALP])</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory.
(ALP = alkaline phosphatase)</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.40" spread="23.26"/>
                    <measurement group_id="O2" value="75.55" spread="25.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.35" spread="47.20"/>
                    <measurement group_id="O2" value="80.42" spread="23.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.77" spread="42.36"/>
                    <measurement group_id="O2" value="4.53" spread="15.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Biochemistry - Creatinine)</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a postbaseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Biochemistry - Creatinine)</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a postbaseline observation.</population>
          <units>Umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.1" spread="15.4"/>
                    <measurement group_id="O2" value="72.3" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.5" spread="16.4"/>
                    <measurement group_id="O2" value="73.1" spread="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="11.0"/>
                    <measurement group_id="O2" value="0.8" spread="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Biochemistry - Lactate Dehydrogenase [LDH])</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory (LDH = lactate dehydrogenase)</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Biochemistry - Lactate Dehydrogenase [LDH])</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory (LDH = lactate dehydrogenase)</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.1" spread="47.8"/>
                    <measurement group_id="O2" value="159.4" spread="57.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164.9" spread="62"/>
                    <measurement group_id="O2" value="162.7" spread="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="45"/>
                    <measurement group_id="O2" value="2.6" spread="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Biochemistry - Potassium)</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Biochemistry - Potassium)</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.46" spread="0.44"/>
                    <measurement group_id="O2" value="4.37" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.49" spread="0.49"/>
                    <measurement group_id="O2" value="4.43" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.50"/>
                    <measurement group_id="O2" value="0.06" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Biochemistry - Sodium)</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Biochemistry - Sodium)</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.9" spread="2.6"/>
                    <measurement group_id="O2" value="139.2" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140.3" spread="2.4"/>
                    <measurement group_id="O2" value="140.0" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="2.8"/>
                    <measurement group_id="O2" value="0.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Laboratory Values (Change in Biochemistry - Total Protein)</title>
        <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Values (Change in Biochemistry - Total Protein)</title>
          <description>Change from Baseline to Week 52 is calculated from the change in percentage((Week 52 %) - (Baseline %)) per participant, averaged across all participants. Measured in serum at baseline and week 52. Serum samples were analysed at a central laboratory</description>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="0.44"/>
                    <measurement group_id="O2" value="7.24" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.13" spread="0.44"/>
                    <measurement group_id="O2" value="7.19" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline to week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.38"/>
                    <measurement group_id="O2" value="-0.06" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <time_frame>Weeks 0-52</time_frame>
        <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
        <group_list>
          <group group_id="O1">
            <title>NN304</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>NN729</title>
            <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <population>FAS (Full Analysis Set) All randomised subjects exposed to at least one dose of trial product with a post-baseline observation.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Weeks 0-52</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NN304</title>
          <description>Individually adjusted dosage of insulin detemir produced by the NN304 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>NN729</title>
          <description>Individually adjusted dosage of insulin detemir produced by the NN729 process, administered sub-cutaneously (s.c.) 1-2 times daily + Individually adjusted dosage of insulin aspart, administered sub-cutaneously (s.c.) at meals for 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy Mediastinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pancreatitis Relapsing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Portal Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Skull Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemic Unconsciousness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Ketosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bile Duct Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Bone Sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Facial Paresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic Coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="33" subjects_affected="26" subjects_at_risk="164"/>
                <counts group_id="E2" events="37" subjects_affected="31" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="164"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="166"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="30" subjects_affected="10" subjects_at_risk="164"/>
                <counts group_id="E2" events="59" subjects_affected="17" subjects_at_risk="166"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>One or more manuscripts for publication will be prepared in collaboration between Investigator(s) and Novo Nordisk. Novo Nordisk will not suppress or veto publications; however Novo Nordisk reserves the right to postpone publication and/or communication for a short time to protect intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Public Access to Clinical Trials</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

